Introduction
B-ALL is the most common pediatric cancer and is a significant cause of death in children and adults. While current chemotherapeutic regimens produce complete remissions in the majority of pediatric patients, they are less effective in adults. This is likely due to the higher incidence of Ph + B-ALL in adults (30-40%) than in children (1-5%) (1, 2) . Additionally, 10-27% of B-ALL cases have gene-expression profiles that are similar to Ph + leukemias (termed Ph-like) (3, 4) , which also confers poor prognosis. Both Ph + and Ph-like leukemias exhibit elevated oncogenic signaling through tyrosine kinases including ABL, PDGFR and JAK (3) . While the use of the ABL tyrosine kinase inhibitor (TKI) imatinib with chemotherapy has improved the initial complete remission rate in Ph + patients, only 38% of imatinib treated patients survive after 4 years (5). Poor long-term survival is mainly driven by the emergence of TKI resistance due to ABL kinase mutations. The second generation inhibitor dasatinib is active against all imatinibresistant kinase domain mutations, except T315I. However, a subset of patients has been observed to relapse after dasatinib treatment without ABL mutations (6) (7) (8) . These dasatinib resistant cells may survive by activating parallel pathways to maintain growth and survival signals driving patient relapse (9, 10) .
A strategy for treating Ph + and Ph-like patients is to inhibit survival pathways activated by tyrosine kinases. A promising candidate is mTOR, which integrates growth factors and nutrient signals to promote cell survival and proliferation. mTOR is a kinase that exists in two complexes, mTORC1 and mTORC2, with distinct mechanisms of activation and downstream outputs. mTORC2 is activated by signals from phosphoinositide 3-kinase (PI3K) and promotes activation of the pro-survival protein AKT (11, 12) . mTORC1 phosphorylates various substrates including ribosomal S6 kinases (S6Ks) and eIF4E-binding proteins (4E-BPs) to promote 5 metabolic pathways that support survival, growth and proliferation (13) . Indeed, high 4E-BP1 phosphorylation correlates with increased relapse in B-ALL patients (14) . While first generation allosteric mTOR inhibitors (rapamycin and its derivatives, rapalogs) only partially inhibit mTORC1, newer ATP-competitive mTOR kinase inhibitors (TOR-KIs) fully suppress mTOR kinase activity in both complexes (15) .
A growing body of evidence indicates that mTOR inhibitors are most effective against cancer cells when used in combination with other agents. For example, TOR-KIs can sensitize B-ALL cells to targeted agents like dasatinib and HDAC inhibitors (16) (17) (18) . In addition, rapamycin can sensitize B-ALL cells to various chemotherapeutic agents (19) (20) (21) . Clinical trials of mTOR inhibitors in combination with chemotherapy in B-ALL patients are underway (22) . In this study, we specifically addressed whether mTOR inhibition sensitizes Ph + and Ph-like B-ALL to chemotherapy. Upon combining standard chemotherapeutic agents with mTOR inhibitors, we noted that mTOR inhibition protected cells from methotrexate (MTX) and 6-mercaptopurine (6-MP), antimetabolites mainly used in maintenance chemotherapy. Protection was seen in vitro and in vivo, resulting in faster relapse following cessation of chemotherapy. The mechanism of protection was largely due to slowing cell cycling. In support, both the cell cycle inhibitor palbociclib and mTOR inhibition markedly reduced the amount of DNA damage caused by MTX and 6-MP. Thus, our data suggest that concurrent treatment with mTORC1-targeted agents and certain maintenance drugs may be counterproductive in Ph + and Ph-like B-ALL patients.
Moreover, inhibitors that target kinases upstream of mTORC1 also protect from maintenance drugs depending on how strongly they inhibit downstream mTORC1 activity. Indeed, dasatinib can also be chemoprotective in B-ALL cells where it suppresses mTORC1 activity. These 6 findings highlight that cell cycle inhibition by targeted oncology drugs can cause unintended protective effects when used in certain chemotherapeutic combinations.
Materials and Methods

Chemicals
Dasatinib, GDC-0941, AZD8055, rapamycin and MLN0128 were obtained from LC Laboratories (Woburn, MA); AKT inhibitor VIII from Chemdea (Ridgewood, NJ). InSolution Q-VD-OPh was from EMD Millipore (Billerica, MA); vincristine, doxycycline, etoposide, daunorubicin, MTX, 6-MP, dexamethasone and araC are from Sigma-Aldrich (St. Louis, MO).
Palbociclib was purchased from Selleck Chemicals (Houston, TX).
Cell Culture
BV-173 cells were purchased from DSMZ (August 2012) and SUP-B15 from ATCC (August 2016) and validated by STR profiling (University of Arizona core facility) on March 2017. B-ALL lines are cultured in RP10 media (RPMI1640 supplemented with 10% FBS, 2 mM Lglutamine, 100 U/mL Pen/strep, and 10 mM HEPES) and used within 3 months of resuscitating viably frozen aliquots.
The Ph-like B-ALL specimen PAUXZX was obtained from the Children Oncology Group through biology protocol AALL16B3-Q. PAUXZX, SFO2, ICN1, and MXP5 B-ALL patient derived xenograft (PDX) lines were cultured as described previously (23) . Briefly, cells were cultured on irradiated OP9 stroma in primary media [MEM Alpha (Gibco Cat. No. 12561-056) supplemented with 20% FBS, 1 mM sodium pyruvate, 1X GlutaMAX (Invitrogen), and 100 U/mL Pen/strep]. OP9 cells were irradiated at 2500 Rad and plated onto gelatin-coated T25 flasks one day prior to plating the B-ALL patient cells. Flasks were pre-coated with 1% gelatin Maximum Sensitivity Substrate (Life Technologies) and Nikon D700 SLR camera system (24) were used to develop the blots. Images were processed using Adobe Photoshop and densitometry was quantified using ImageJ software.
Intracellular Flow Cytometry
To detect mTORC1 activity, 5×10 Cells were resuspended in 150 μL PBS for FACS analysis.
Cell Cycle Assay
Cells were plated at 2×10 
Animals
Mice were studied in compliance with protocols approved by the Institutional Animal Care and Use Committees of the University of California, Irvine.
4E-BP1 5A inducible p190 cells
Using Rosa26-rtTA control mice and Rosa26-rtTA/TRE-4E-BP1 5A mice described in So et al (25), we made pre-B leukemia cells (p190 cells) driven by the p190 isoform of BCR-ABL as described in Kharas et al (26) .
In vitro regrowth assay
Cell lines were plated at 2.5 ×10 and PI. Cells were ran on BD FACSCalibur to count number of viable cells at equal flow rates and time collected, similar to growth rate method described above. The number of viable cells was calculated using the viable events counted and passaging records.
In vivo xenograft
NSG mice were obtained from JAX (NOD-SCID-IL2Rγ-null, stock 005557). Animal studies were approved by the Institutional Animal Care and Use Committee at UC Irvine. NSG mice at 1-3 months of age were retro-orbital injected with 2.5 million SFO2 or PAUXZX patient cells.
Facial vein bleeds were done to monitor engraftment. Upon detection of greater than 1% leukemia was observed in all mice, mice were dosed once daily for 5 days with 30 mg/kg 6-MP, 20 mg/kg AZD8055, 10 mg/kg dasatinib, or combinations. 6-MP was dissolved in 0.5% carboxymethylcellulose (medium viscosity, Sigma) in water and injected with a 26 gauge-needle by intraperitoneal injection. AZD8055 was given orally in 0.5% hydroxypropylmethylcellulose with 0.1% Tween-80 in water. Dasatinib was given orally dissolved in a 50:50 mix of polypropylene glycol and water. Dosing schedules are outline in Figure 6A for PAUXZX and 6D for SFO2.
After final dosing on day 5, control mice were given one day of rest to clear dying cells that would make accurate detection of leukemia burden difficult. Post-treatment mice given only single agents controls or vehicle were sacrificed on day 7. Two hours before sacrifice, single agent (vehicle, AZD8055 and dasatinib) control mice were dosed one more time to detect inhibitor effects on mTORC1 signaling.
Relapse mouse sets were monitored by facial bleeds for signs of leukemia relapse. Upon detection of more than 1% leukemia in peripheral blood of any group, all relapse sets were sacrificed at once.
Bone marrow and spleen were obtained. Red blood cells were lysed in ACK buffer (150 mM NH 4 Cl, 10 mM KHCO 3 and 0.1 mM Na 2 EDTA in water) for 5 minutes at room temperature and washed with cold PBS + 1% FBS. One million cells were stained with human CD19-PE (Biolegend clone HIB19) and mouse CD45-APC (eBioscience clone 30-F11) for 20 minutes on ice in PBS + 1% FBS. Cells were spun down at 500 × g for 5 minutes and resuspended in cold PBS for FACS analysis. Remaining samples were analyzed according to Western blot section above.
Results
Inhibition of mTORC1 protects from MTX and 6-MP
Since high mTORC1 activity is predictive of increased relapse in B-ALL patients, we tested whether inhibiting mTOR would sensitize B-ALL cell lines to chemotherapeutic agents. Using MLN0128 (a TOR-KI compound), we found that mTOR inhibition protected Ph+ B-ALL cell lines BV173 and SUP-B15 from the cytotoxic effects of both MTX and 6-MP ( Fig. 1A and B) .
A titration of rapamycin, MLN1028 (27) and AZD8055 (28) (a chemically distinct TOR-KI) revealed that all mTORC1 inhibitors protect from MTX in a dose-dependent manner ( Supplementary Fig. S1A ). Moreover, mTOR inhibition shifted the dose response curve for MTX and 6MP towards greater survival even at higher doses ( Supplementary Fig. S1B ).
Treatment with MLN0128 alone did not affect viability of BV173 or SUP-B15 (Supplementary Fig. S1A and D) . The dual PI3K/mTOR inhibitor NVP-BEZ235 also exhibited protection ( Supplementary Fig. S1C ).
To confirm that mTOR inhibition preserves more viable cells, we assessed the outgrowth of leukemia cells after treatment cessation. Therefore, we treated BV173 and SUP-B15 cells with MTX in presence or absence of mTOR inhibition for 3 days. Cells were allowed to regrow for 7 days in the absence of drug. Indeed, mTOR inhibition combined with MTX increased the number of recovered cells compared to MTX alone ( Supplementary Fig. S1E and F, note the log scale).
We further tested these combinations on B-ALL lines (Supplementary Table S1 ) established as patient-derived xenografts (PDX) and then grown on OP9 stromal cells. mTOR inhibition protected from killing by MTX and 6-MP in the Ph-like sample PAUXZX as well as two Ph + samples ICN1 and SFO2 (Fig. 1C and D) . In a third Ph + sample, MXP5, MLN0128 slightly rescued from killing by 6MP but not MTX. mTOR inhibition had variable affects on the cytotoxicity of other chemotherapeutic agents in BV173 and SUP-B15 cell lines ( Supplementary Fig. S2A and B), with slight but statistically significant protection observed for some agents, for example araC. However, we did not observe similar protection from araC in any of the PDX lines ( Supplementary Fig. S2C ). Together these results show that in both cell lines and stromal-dependent B-ALL cells, mTOR inhibition consistently protects from killing by MTX and 6-MP but not other chemotherapeutic agents.
Inhibition of kinases upstream of mTOR protects B-ALL cells
Inhibitors of various kinases in the PI3K/AKT/mTOR network are actively being explored as therapeutic agents ( Fig. 2A) (15, (29) (30) (31) . We tested if these inhibitors would similarly have the adverse effect of chemoprotection. We titrated each inhibitor to find the minimum concentration needed to fully and selectively inhibit its intended target ( Supplementary Fig. S3 ), then treated the Ph + cell line BV173 with each inhibitor in the presence or absence of MTX (Fig. 2B and C) .
No inhibitor caused cell death as a single agent. However, when combined with MTX, most inhibitors protected from the chemotherapy agent. Notably, direct mTORC1 inhibitors (MLN0128, rapamycin) provided the greatest protection. The TKI dasatinib, which blocked p-STAT5 and reduced mTOR signaling in BV173 cells (Fig. 2B) , also protected from MTX.
Quantifying mTOR inhibition by intracellular staining of S6 phosphorylation (Fig. 2D) revealed that the degree of mTORC1 inhibition by each compound correlates with how well it protects from MTX (Fig. 2E) . These effects were not restricted to BV173 cells since upstream inhibitors also protected from MTX in Ph + SUP-B15 cells (Fig. 2F) . Notably, dasatinib minimally affected p-S6 in SUP-B15 cells despite fully suppressing STAT5 phosphorylation. Correspondingly, dasatinib did not protect SUP-B15 from MTX but rather enhanced the effect of the chemotherapy (Fig. 2F, lower graph) . Thus, inhibition of mTORC1 either directly or indirectly can be protective.
Dasatinib protects only when it inhibits mTORC1
Currently, TKIs improve the clinical outcome of most Ph + B-ALL patients when added to the standard chemotherapy regimen (5). However, our data suggest that dasatinib may be chemoprotective in some contexts (Fig. 2C) . Therefore, we evaluated the context where TKIs like dasatinib would be counterproductive. At a dose of 3 nM dasatinib, which was sufficient to inhibit phosphorylation of ABL and STAT5 ( Supplementary Fig. S4A and B) , dasatinib did not reduce mTORC1 activity and correspondingly sensitized SUP-B15 cells to all chemotherapies tested ( Fig. 3A and B) . Rapamycin was used as a positive control to suppress pS6 downstream of mTORC1 (Fig. 3B) . However, in BV173 cells, where dasatinib suppressed mTORC1 activity, dasatinib protected from 6-MP and MTX (Fig. 3C and D) . Using a cell counting assay, we confirmed that dasatinib and MLN0128 protected from 6-MP and MTX in BV173 cells whereas only MLN0128 protected in SUP-B15 cells (Supplementary Figure S4C -F Fig. S5C and D) . Overall, these results suggest that protection from 6-MP by dasatinib is only observed in B-ALL cells where dasatinib is not cytotoxic and mTOR is inhibited.
Protection by mTOR inhibition correlates with cell cycle inhibition
Since MTX and 6-MP both inhibit production of nucleotides necessary for cell proliferation, we tested whether protection by mTORC1 inhibition correlated with slowing of cell proliferation. By counting the accumulation of cells after 72 hours, we found that the degree of growth inhibition by different mTORC1 inhibitors significantly correlated with the degree of protection from both MTX and 6-MP (Fig. 4A and B) . Notably, dasatinib reduced cell growth to a similar extent as MLN0128 in BV173 (Fig. 4C) , where it protected from MTX. However, dasatinib did not greatly reduce growth of SUP-B15 cells, where it is not protective.
To determine whether cell cycle inhibition was sufficient to protect B-ALL cells from maintenance drugs, we used the CDK4/6 inhibitor, palbociclib (32) , to selectively inhibit cell cycling without suppressing mTORC1. Similar to mTOR inhibition (Fig. 4D) , palbociclib caused dose-dependent G1 arrest (Fig. 4E ) and protection from MTX (Fig. 4F) without affecting viability as a single agent (Supplementary Fig. S6 ). Aphidicolin (33) , which causes early S phase arrest, similarly protected against MTX in a dose dependent manner ( Fig. 4G and H) . Thus, cytotoxicity of maintenance drugs is highly affected by cell cycle inhibition.
The 4E-BP-eIF4F axis downstream of mTORC1 regulates protein translation and cell cycle progression (34, 35) . Active mTORC1 phosphorylates the 4E-BPs, inhibiting their ability to suppress the formation of the eIF4F translation initiation complex. Therefore, we tested whether inhibition of eIF4F function through 4E-BP activity was sufficient to cause G1 arrest and protect from maintenance drugs. We utilized mice expressing the reverse tetracycline transactivator (rtTA) under control of the Rosa26 promoter. Additionally, the mice have a mutant form of 4E-BP1, which has all five of its mTORC1 phosphorylation sites mutated to alanines (termed "4E-BP1 5A") (36), controlled by a tetracycline responsive element (TRE) (25, 37) . This 4E-BP1 5A cannot be phosphorylated by mTOR, allowing it to constitutively suppress eIF4F formation.
From these mice, we generated pre-B leukemia cells driven by the p190 isoform BCR-ABL (termed p190 cells) (26, 38) , where expression of 4E-BP1 5A can be induced by the addition of doxycycline (Dox, Fig. 5A ).
Dox induction of 4E-BP1 5A expression caused cell cycle arrest in p190 cells similar to MLN0128 and palbociclib treatment (Fig. 5B and C) . Dox had no effect in RosaA26-rtTA 18 control cells (Fig. 5D ). In the 4E-BP1 5A inducible p190 cells MLN0128, Dox, and palbociclib protected cells from MTX and 6-MP (Fig. 5E) , suggesting that the 4E-BP axis can account for most of the cell cycle and protective effects of mTOR inhibition.
Cell cycle inhibition reduces DNA damage by maintenance drugs
MTX and 6-MP cause DNA breaks, which activates ATR leading to the phosphorylation of Chk1 (39, 40) . Therefore, we asked whether cell cycle inhibition reduces DNA damage by these drugs. We measured DNA damage caused by MTX using phosphorylation of histone H2A.X as a DNA damage marker. We added the pan-caspase inhibitor QVD-OPh to eliminate apoptosismediated DNA damage. After 48 hours, MTX increased p-H2A.X in both BV173 and SUP-B15 cells, which was reduced by addition of MLN0128 ( Supplementary Fig. S7A and B) . However, dasatinib only reduced the amount of DNA damage in BV173 but not in SUP-B15 cells, suggesting that this effect is dependent on suppression of mTORC1 activity and cell proliferation.
To determine whether cell cycle inhibition without mTORC1 inhibition is sufficient to reduce DNA damage by maintenance drugs, we treated BV173 and SUP-B15 cells with 6-MP or MTX with increasing concentrations of palbociclib. Both 6-MP and MTX caused single stranded DNA breaks indicated by phosphorylation of Chk1. Increasing concentrations of palbociclib decreased p-Chk1 and p-Histone H2A.X ( Supplementary Fig. S7C and D) . Similarly, p-Chk1 and p-histone H2A.X were not observed in in the presence of MLN1028. Thus, cell cycle inhibition is sufficient to reduce DNA damage by 6-MP and MTX. In agreement, others have found that palbociclib protected cells from irradiation-induced DNA damage (41) .
mTOR inhibition increases relapse after 6-MP treatment in vivo
To determine whether mTOR inhibition protects B-ALL cells from 6-MP in an in vivo model, we injected Ph-like PAUXZX cells into immunodeficient NOD-SCID-IL2Rγ -/-(NSG) mice. After engraftment was detected in the NSG mice, we treated mice with 6-MP, the mTOR kinase inhibitor AZD8055, or the combination for 5 days. After treatment, we sacrificed control vehicle and AZD8055 treated mice and verified that mTOR was indeed inhibited in the spleen cells of AZD8055 treated mice (Fig. 6A and B) . Three days after the last dose, we sacrificed the 6MP and 6MP+AZD groups to determine leukemic burden. Both male and female mice were used in this experiment to determine if gender has an effect on the outcome. In both male and female mice, AZD8055 significantly increased the percentage of leukemia cells in the bone marrow (Fig. 6C) . Thus in a Ph-like B-ALL xenograft, mTOR inhibition protects leukemia from 6-MP leading to faster outgrowth after cessation of treatment.
To determine the effect of dasatinib in vivo, we injected Ph + SFO2 patient cells into NSG mice. Upon detection of leukemia we treated the mice for 5 days with single or combined regimens of 6-MP with AZD8055 or dasatinib (Fig. 6D ). Mice were separated into posttreatment (assess efficacy of drugs as single agents) or relapse groups (assess regrowth effect of drug combinations). After treatment (Day 7), mice post-treatment groups were assessed for leukemia burden and mTOR inhibition. Compared to vehicle, AZD8055 and dasatinib reduced mTORC1 activity in bone marrow cells indicated by a reduction in phosphorylation of 4E-BP1 (Fig. 6E) . Both AZD8055 and dasatinib as single agents slightly reduced leukemic burden (Fig.   6F , Post RX group), presumably due of reduction in cell cycle since neither drug alone is cytotoxic to SFO2 cells in vitro. 6-MP alone greatly reduced the leukemia burden in the bone marrow and spleen of the post-treatment mice.
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Additional groups (6MP only, 6MP+AZD, and 6MP+Das groups) were monitored for relapsing leukemia in the peripheral blood. Mice were sacrificed on day 25 when more than 1% leukemia was detected in peripheral blood. Both AZD8055 and dasatinib significantly increased the leukemic burden in the bone marrow of 6-MP treated mice (Fig. 6F) . Thus, inhibiting mTORC1, either direct or indirectly, can protect B-ALL leukemia cells from 6-MP and accelerate relapse in vivo.
Discussion
We found that direct or indirect mTORC1 inhibition in Ph + and Ph-like B-ALL cells can cause protection from maintenance drugs MTX and 6-MP. ABL, PI3K and AKT inhibitors protect depending on how strongly these inhibitors reduce mTORC1 activity. Since many pathways activate mTOR, these upstream inhibitors vary in how fully they reduce mTOR activity among various cell lines. Importantly, in a subset of Ph Protection by mTORC1 inhibition is in large part due to cell cycle inhibition and prevention of DNA damage. MTX and 6-MP both inhibit the synthesis of nucleotides necessary for DNA replication in dividing cells (40, 42) . Their mechanism of killing therefore is highly dependent on Fig. S8 ). Likely, mTOR inhibition causes antagonizing cell cycle related protection and MTX sensitizing effects, with the overall outcome differing from patient to 22 patient. Whether mTORC1 inhibition rescues survival in distinct subclones of a leukemia remains to be determined. Results from the current trial NCT01162551 of sirolimus and MTX in relapsed/refractory lymphoblastic leukemia will determine if mTOR inhibition predominantly sensitizes or protects from MTX in most B-ALL patients.
The effect of mTOR inhibition on the cytotoxicity of induction phase chemotherapy agents is highly variable. mTOR inhibition tends to be protective in the cases of vincristine and etoposide ( Supplementary Fig. S2 ). It tends to sensitize to daunorubicin. The inconsistencies may be a product of two counteracting effects of mTOR inhibition: cell cycle inhibition and mitochondrial priming. Using BH3 profiling, we previously found that mTOR inhibition affects the BCL-2 family of proteins to make B-ALL cells more sensitive to apoptosis initiation signals at the mitochondria ("mitochondrial priming") (16) . However for a cytotoxic drug that is highly cell cycle dependent, mTOR inhibition slows cell cycling to prevent cellular damage and apoptosis initiation signals are not even triggered. Though this model needs further validation, it can explain why mTOR inhibition sensitizes to dasatinib and HDAC inhibitors (16, 18) , which are not dependent on cell cycling to initiate apoptosis. For induction chemotherapy drugs, the outcome of these competing effects is hard to predict. A Phase I/II study has shown that mTOR inhibitor everolimus combined with intensive HyperCVAD induction chemotherapy provided no significant improvement compared to historical response to HyperCVAD alone in B-ALL patients, while improvement was only seen in T-ALL cases (22) . Trials testing other induction regimens with mTOR inhibitors are underway (NCT01614197 and NCT01523977).
Kano and colleagues found that BCR/ABL inhibitor STI571 (imatinib) protects the Ph + chronic myeloid leukemia cell line KU812 from methotrexate (44) . Similarly, we found that dasatinib can protect against 6-MP in Ph Viability is measured by Annexin-V and PI staining. Unpaired t-tests of were performed, n=3, mean±SD, *p<0.05, **p<0.005, ***p<0.0005. assays, controls were mTOR inhibitor (100 nM MLN0128) or cell cycle inhibitor (300 nM palbociclib). Unpaired t-tests of "chemo" versus "chemo+inhibitor" were performed for each drug in cell cycle and viability assays, n=3, mean±SD, *p<0.05, **p<0.005, ***p<0.0005. The bone marrow and spleen of the control "post-treatment" and experimental "relapse" mice were obtained. The percentage of leukemia in bone or spleen were detected by staining human CD19 versus mouse CD45. Unpaired t-test was done for each comparison, mean±SD, *p<0.05, **p<0.005, ***p<0.0005.
